NTLA Key Statistics, Chart & Performance
The current stock price of NTLA is 11.09 USD. In the past month the price increased by 9.48%. In the past year, price increased by 13.28%.
NTLA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NTLA. When comparing the yearly performance of all stocks, NTLA is one of the better performing stocks in the market, outperforming 76.08% of all stocks.
NTLA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NTLA. No worries on liquidiy or solvency for NTLA as it has an excellent financial health rating, but there are worries on the profitability.
NTLA Financial Highlights
Over the last trailing twelve months NTLA reported a non-GAAP Earnings per Share(EPS) of -4.27. The EPS increased by 21.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.18% | ||
| ROE | -59.57% | ||
| Debt/Equity | 0 |
NTLA Forecast & Estimates
31 analysts have analysed NTLA and the average price target is 17.72 USD. This implies a price increase of 59.81% is expected in the next year compared to the current price of 11.09.
For the next year, analysts expect an EPS growth of 23.1% and a revenue growth 7.96% for NTLA
NTLA Ownership
NTLA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.08 | 383.716B | ||
| AMGN | AMGEN INC | 16.32 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.72 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.25 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.25 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NTLA
Company Profile
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 403 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Company Info
INTELLIA THERAPEUTICS INC
40 Erie St Ste 130
Cambridge MASSACHUSETTS 02139 US
CEO: John M. Leonard
Employees: 403
Phone: 18572856200
INTELLIA THERAPEUTICS INC / NTLA FAQ
What does INTELLIA THERAPEUTICS INC do?
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 403 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
Can you provide the latest stock price for INTELLIA THERAPEUTICS INC?
The current stock price of NTLA is 11.09 USD. The price decreased by -10.28% in the last trading session.
What is the dividend status of INTELLIA THERAPEUTICS INC?
NTLA does not pay a dividend.
What is the ChartMill rating of INTELLIA THERAPEUTICS INC stock?
NTLA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of NTLA stock?
INTELLIA THERAPEUTICS INC (NTLA) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of NTLA stock?
INTELLIA THERAPEUTICS INC (NTLA) has a market capitalization of 1.28B USD. This makes NTLA a Small Cap stock.
What is the Short Interest ratio of INTELLIA THERAPEUTICS INC (NTLA) stock?
The outstanding short interest for INTELLIA THERAPEUTICS INC (NTLA) is 38.52% of its float.